Member Info for Fanti

Best advice possibly is to forget about CTA application and trust on the reminder of assets in the pipe. Even though we are supposed to be best in class we were not first in class on the same active substance and subject ie. Psoriasis. Fact. Who knows if that not matters?
CTA application and its approval was nice to have but given the circumstances - UK institution and BOD seem paralysed since month' - the current share IMHO is fairly valued whether now with or w/o CTA approval given no revenue but a lot of justified hope on our assets and forthcoming business (SRA 737) already priced in.
GLA

Here we go again.

I sold 510 shares @1:41pm. Not showing up I may have crashed any algorithm.
Apologies!!

Speculation likewise can be that both the regular 5k and 2k buyer are the same guy or institution.

What it needs now is confirmation of CTA application. That ll be a fair signal to us investors and also to Pharma's. MK lost over the course still by a 40?%.
I start to wonder if BoD simply don't cares is blind or has no advisors or if ignorance is simply helpful for what so ever purpose one might speculate on.

worse should have meant worth.

On July, 17th CTA Application to MHRA was worth to drop an RNS. Is it not worse now when we did apply anywhere else as we presume? I remember, the BOD promised an update in due course.
Now, what are you guys waiting for?

Looking at the share price someone is happy to buy in that cheap right now. Fair enough, but any interested party could be busy collecting a substantial holding. Institutional investors?
Starting from scratch one only would need approx need at around 41 -60 days ? to rule over 3% (2.042k) shares when he or she successfully buys on average
50k shares on 40 days
60k shares on 24 days
80k shares on 26 days.

Question is who is buying? I have doubt its us LTH.

The comment on Marketscreener has been revised and is now more precise on the year. If that is not funny.

Many thanks, Ahfam, for providing a shed of light.

Is Merck now sorted or could they well be interest on us?

MERCK:
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a =4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)

https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-as-adjuvant-treatment-following-surgical-resection-and-platinum-based-chemotherapy-for-patients-with-stage-ib-t2a-=4-centimeters-ii-or-iiia-non/

I see what you are saying we are going up anyway. :). We think but once we close this GAP here chances are good to climb higher even better.
No expert at all. Though, GAPs on a lower level not necessarily need to be filled, I guess.

i s

Never mind anyone's strategy, yet he 's rightly referring to the GAPs close with another one looming @1,75 BTW.

Morning SOG, your input and constructive insight into science is much appreciated. Thx a mill following up.

If the source can be trusted, since nothing to be found on their site? Don' be fooled. Don't think we ever had kind of a forecast, hadn'd we?

Considering 5 Billion revenue that could justify 3.5 GBP with a multiple of 7. Very conservative calculation that is though, I think.

https://m.marketscreener.com/quote/stock/SAREUM-HOLDINGS-PLC-4004879/news/Sareum-Holdings-plc-Provides-Revenue-Guidance-for-the-Fiscal-2023-42842109/

https://m.marketscreener.com/quote/stock/SAREUM-HOLDINGS-PLC-4004879/news/Sareum-Holdings-plc-Raises-Sales-Guidance-for-the-Fiscal-2025-42842110/

The trial (ClinicalTrials.gov identifier NCT02797977, EudraCT Number: 2015–004467–36) was conducted at 21 centers in the UK and Spain between August 3, 2016 and April 8, 2020.

Article dated from January, 17th.
Sorry, if already posted.

https://aacrjournals.org/clincancerres/article/29/2/331/713982/A-Phase-I-II-Trial-of-Oral-SRA737-a-Chk1-Inhibitor

If January 12th was the day of termination we possibly have to allow further 14 days to hand everything back. Meaning SO could well be delivering on time by tonight me rhinks.

15.1.11 ProNAi shall, at CPF’s cost, within fourteen (14) days of the date of termination of this Agreement disclose to CPF (or its nominee) all Arising Intellectual Property.

Cheers mates, quite helpful information that is. I always thought patents were already granted to find out that was not say is not the case at the time they gave notice and ip until now. If thats not way risky to terminate contract given these ongoing matters.

Hardly to believe but is SO temporarily awaiting approval of their patents?
This patent looks been successfully filed back in in Oct 2022. Another application at the European Patent office is currently pending.
Might be possible wrong information pulled.

Chk1 (SRA737)/PARPi combination methods of inhibiting tumor growth
WO EP US CN JP KR AU CA MX AU2022259818A1 Christian Andrew HASSIG Sierra Oncology, Inc.
Priority 2017-04-10 • Filed 2022-10-27 • Published 2022-12-01
Herein disclosed are combinations of Checkpoint Kinase 1 (Chkl) inhibitors and PARP inhibitors useful for inhibiting the growth of tumors such as those in patients with cancer. In particular, the combination demonstrates remarkable synergistic effects on cancer cells that are representative models …

https://patents.google.com/patent/EP3609884A1/en

Did anyone else notice the latest CTA for 1801? Chart reads like we are awaiting approval for both the targets with C19 new as a matter of fact. Official website is telling different story and RNS we didn't have either. What we need is an update either here or there. Puzzled.